United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
October
11, 2019
Date
of Report (Date of earliest event reported)
Chardan
Healthcare Acquisition Corp.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-38762
|
|
82-3364020
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
17 State Street, 21st Floor New York, NY
|
|
10004
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code: (646) 465-9000
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425
under the Securities Act
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbols
|
|
Name
of each exchange on which registered
|
Units,
each consisting of one share of common stock, $0.0001 par value, and one Warrant
|
|
CHAC.U
|
|
NYSE
American
|
Common
stock, $0.0001 par value per share
|
|
CHAC
|
|
NYSE
American
|
Warrants
to purchase common stock
|
|
CHAC.WS
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
IMPORTANT
NOTICES
Participants
in the Solicitation
BiomX
Ltd. (“BiomX”), Chardan Healthcare Acquisition Corp. (“CHAC”), and their respective directors, executive
officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of CHAC
common stock in respect of the proposed transaction described herein. Information about CHAC’s directors and executive officers
and their ownership of CHAC’s common stock is set forth in CHAC’s Prospectus dated December 14, 2018 and CHAC’s
proxy statement on Schedule 14A dated September 23, 2019 filed with the Securities and Exchange Commission (the “SEC”),
as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding
the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed
transaction when it becomes available. These documents can be obtained free of charge from the sources indicated below.
Additional
Information and Where To Find It
In
connection with the transaction described herein, CHAC has filed relevant materials with the SEC, including a proxy statement
on Schedule 14A. CHAC mailed the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special
meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF CHAC ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT CHAC WILL FILE WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CHAC, BIOMX AND THE TRANSACTION. The definitive proxy
statement and other relevant materials in connection with the transaction (when they become available), and any other documents
filed by CHAC with the SEC, may be obtained free of charge at the SEC’s website (www.sec.gov) or by writing to Chardan Healthcare
Acquisition Corp., 17 State Street, 21st Floor, New York, NY 10004.
Forward-Looking
Statements
This
Current Report on Form 8-K and the documents incorporated by reference herein (this “Current Report”) contain certain
“forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,”
“expect,” “will,” “shall,” “may,” “anticipate,” “estimate,”
“would,” “positioned,” “future,” “forecast,” “intend,” “plan,”
“project” and other similar expressions that predict or indicate future events or trends or that are not statements
of historical matters. Examples of forward-looking statements include, among others, statements made in this Current Report regarding
the proposed transactions contemplated by the merger agreement (the “Merger Agreement”) among CHAC, CHAC Merger Sub
Ltd. and BiomX (the “Merger”), including the anticipated initial enterprise value and post-closing equity value, the
benefits of the Merger, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating
performance and results, including estimates for growth, the expected management and governance of the combined company, and the
expected timing of the Merger. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,
they are based only on CHAC and BiomX managements’ current beliefs, expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult
to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors
that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include,
among others, the following: (1) the occurrence of any event that could give rise to the termination of the Merger Agreement;
(2) the outcome of any legal proceedings that may be instituted against CHAC, the combined company, or others following the announcement
of the Merger and the Merger Agreement; (3) the inability to complete the Merger due to the failure to obtain approval of CHAC’s
stockholders or to satisfy other conditions to closing in the Merger Agreement; (4) changes to the proposed structure of the Merger
that may be required or appropriate as a result of applicable laws; (5) the ability to meet NYSE American listing standards following
the consummation of the Merger; (6) the risk that the Merger disrupts current plans and operations of BiomX as a result of the
announcement and consummation of the Merger; (7) the ability to recognize the anticipated benefits of the Merger, which may be
affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain
relationships with third parties and partners, obtain adequate supply of raw materials and retain its management and key employees;
(8) costs related to the Merger; (9) changes in applicable laws or regulations; (10) the possibility that BiomX or the combined
company may be adversely affected by other economic, business, regulatory, and/or competitive factors; (11) BiomX estimates of
expenses; (12) the impact of foreign currency exchange rates and interest rates fluctuations on the results of BiomX or the combined
company; and (13) other risks and uncertainties indicated in the proxy statement of CHAC filed by CHAC with the SEC in connection
with the Merger, including those under “Risk Factors” therein, and other documents filed or to be filed from time
to time with the SEC by CHAC.
A
further list and description of risks and uncertainties can be found in CHAC’s Prospectus dated December 14, 2018 filed
with the SEC and in the proxy statement on Schedule 14A that has been filed with the SEC by CHAC in connection with the proposed
transaction dated September 23, 2019, and other documents that the parties may file or furnish with the SEC, which you are encouraged
to read. Any forward-looking statement made by us in this Current Report is based only on information currently available to CHAC
and BiomX and speaks only as of the date on which it is made. CHAC and BiomX undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments
or otherwise, except as required by law.
Item
1.01. Entry Into a Material Definitive Agreement
As
previously announced, on July 16, 2019, Chardan Healthcare Acquisition Corp. (“CHAC”) entered into a merger agreement
(the “Merger Agreement”) with CHAC Merger Sub Ltd., a wholly-owned subsidiary of CHAC (the “Merger Sub”),
and BiomX Ltd. (“BiomX”).
On
October 11, 2019, CHAC, Merger Sub and BiomX entered into an amendment to the Merger Agreement (the “Amended Merger Agreement”)
to reflect the following:
|
●
|
Among
other things, as a condition to the obligations of BiomX to consummate the transactions
contemplated by the Merger Agreement, the Aggregate Investment Amount (as defined in
the Merger Agreement) shall equal or exceed $55 million.
|
|
●
|
The
agreement of Chardan Investment LLC to cancel up to 500,000 CHAC Shares in the event
that the Aggregate Investment Amount (as defined in the Merger Agreement) is less than
$70 million at the closing of the Business Combination (as defined in the Merger Agreement)
was terminated.
|
|
●
|
CHAC
and BiomX have agreed to extend the Outside Closing Date (as defined in the Merger Agreement)
to November 30, 2019.
|
In addition, the agreement pursuant to which
Chardan Securities, LLC agreed to purchase up to $2.5 million of CHAC Shares at the closing of the Business Combination in the
event that the Aggregate Investment Amount is less than $50 million has been amended such that Chardan Securities, LLC agrees to
purchase up to $2.5 million of CHAC Shares (as defined in the Merger Agreement) at the closing of the Business Combination in the
event that the Aggregate Investment Amount is less than $55 million, provided that CHAC shall not be obligated to make such purchases
to the extent that the Aggregate Investment Amount is less than $55 million because of the failure of the BiomX shareholders to
purchase $23 million of CHAC Shares.
On October 11, 2014, CHAC filed an supplement
to its proxy statement on Schedule 14A with the SEC describing these amended terms.
Item 3.02 Unregistered Sales of Equity Securities
The disclosure set forth above in Item 1.01 of this Current Report
on Form 8-K is incorporated by reference herein. The securities of CHAC to be issued in connection with the Merger and additional
agreements will not be registered under the Securities Act in reliance upon the exemption provided in Section 4(a)(2) of the Securities
Act.
Item 7.01 Regulation FD Disclosure
Attached as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated into this Item 7.01 by reference is a copy of the press release issued October 11, 2019 announcing the amendments
to the proposed transaction.
Exhibit 99.1 is being furnished pursuant to Item 7.01 and shall
not be deemed to be filed for purposes of Section 18 of the Exchange Act or otherwise be subject to the liabilities of that section,
nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.
Item
9.01. Financial Statements and Exhibits
(d) Exhibits.
*Furnished but not filed.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated
October 11, 2019
CHARDAN
HEALTHCARE ACQUISITION CORP.
Name:
Jonas Grossman
Title: President and Chief Executive Officer
4
Chardan Healthcare Acqui... (AMEX:CHAC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chardan Healthcare Acqui... (AMEX:CHAC)
Historical Stock Chart
From Jul 2023 to Jul 2024